Sotera Health Q4 Earnings Call Highlights

• 2 Sizzling Mid-Caps That Could Stay Hot This Summer

Sotera Health (NASDAQ:SHC) reported gross maturation and borderline enlargement successful 2025, extending what absorption said is simply a 20-year way grounds of year-over-year gross increases, portion besides outlining expectations for continued maturation and higher net successful 2026.

Chairman and CEO Michael Petras said full institution gross accrued 5.7% successful 2025 to $1.164 billion, oregon 5.2% connected a constant-currency basis. Adjusted EBITDA roseate 8.2% (7.8% changeless currency) to $593.8 million, and adjusted EBITDA borderline expanded to 51%, an summation of astir 120 ground points twelvemonth implicit year. The institution besides reported adjusted escaped currency travel of much than $200 cardinal for the year, which CFO Jon Lyons quantified astatine $210 million.

→ Gold and Silver Pulled Back—Here’s Why the Bull Case Is Intact

• Here’s Why Sotera Health Company Stock Just Doubled successful a Day

Lyons said reported nett income for 2025 was $78 million, oregon $0.27 per diluted share. Adjusted EPS was $0.86, up $0.16 from 2024, driven by operating growth, a little taxation complaint and improved involvement expense, partially offset by higher depreciation.

In the 4th quarter, Sotera Health reported gross of $303 million, up 4.6% twelvemonth implicit twelvemonth (2.5% changeless currency). Adjusted EBITDA accrued 2.7% to $157 million, with adjusted EBITDA borderline of 51.8%.

→ Hinge Health’s AI Moat Might Be Its Patient Movement Data

Lyons said the quarterly examination reflected “the expected interaction of Cobalt-60 harvest timing astatine Nordion.” Interest disbursal was $35 million, a $6 cardinal betterment from the year-ago quarter. Net income was $35 million, oregon $0.12 per diluted share, portion adjusted EPS accrued to $0.26, up $0.05 from the anterior year, aided by a little taxation complaint and little involvement disbursal and partially offset by higher depreciation.

• Sterigenics: Q4 gross grew 10.6% to $198 cardinal (8% changeless currency). Growth was driven by 4.3% favorable pricing and 3.7% measurement and mix, positive a 2.6% overseas currency benefit. Segment income roseate 10.4% to $110 million.

• Nordion: Q4 gross declined 12.3% to $50 cardinal owed to harvest-schedule timing that drove 15% unfavorable measurement and mix, partially offset by 2.4% favorable pricing. Segment income fell 18.9% to $29 million, with borderline down 466 ground points to 57.5%.

• Nelson Labs: Q4 gross accrued 2.3% to $55 cardinal (nearly level changeless currency). Pricing and halfway laboratory investigating maturation were partially offset by little adept advisory services revenue. Segment income roseate 1.9% to $18 million.